José Luis Dapena
Research Subjects
José Luis Dapena has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Díaz de Heredia
Department of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
3 shared publications A. González
1 shared publicationAlejandro A. Schäffer
Computational Biology Branch, National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD
1 shared publicationAlexa Triot
Department of Pediatrics, Division of Pediatric Hematology and Oncology, Dr von Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany
1 shared publicationAna Valls-Lafon
Department of Biochemistry, Hospital Sant Joan de Déu
1 shared publication- Andrea Martín-Nalda
Hospital Universitari Vall d’Hebron Campus
1 shared publication
Latest Publications
- 30 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , e399-e402
BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series
Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.
- 30 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , e399-e402
BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series
Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.
- 1 December 2014
- Published by Elsevier in Anales de Pediatría
- Vol. 81 (6) , e48-e49
Anticuerpos antimúsculo liso sin hepatitis autoinmune
- 1 December 2014
- Published by Elsevier in Anales de Pediatría
- Vol. 81 (6) , e48-e49
Anticuerpos antimúsculo liso sin hepatitis autoinmune
- 12 June 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (24) , 3811-3817
Inherited biallelic CSF3R mutations in severe congenital neutropenia
Severe congenital neutropenia (SCN) is characterized by low numbers of peripheral neutrophil granulocytes and a predisposition to life-threatening bacterial infections. We describe a novel genetic SCN type in 2 unrelated families associated with recessively inherited loss-of-function mutations in CSF3R, encoding the granulocyte colony-stimulating factor (G-CSF) receptor. Family A, with 3 affected children, carried a homozygous missense mutation (NM_000760.3:c.922C>T, NP_000751.1:p.Arg308Cys), which resulted in perturbed N-glycosylation and aberrant localization to the cell surface. Family B, with 1 affected infant, carried compound heterozygous deletions provoking frameshifts and premature stop codons (NM_000760.3:c.948_963del, NP_000751.1:p.Gly316fsTer322 and NM_000760.3:c.1245del, NP_000751.1:p.Gly415fsTer432). Despite peripheral SCN, all patients had morphologic evidence of full myeloid cell maturation in bone marrow. None of the patients responded to treatment with recombinant human G-CSF. Our study highlights the genetic and morphologic SCN variability and provides evidence both for functional importance and redundancy of G-CSF receptor-mediated signaling in human granulopoiesis. Key Points Biallelic mutations in CSF3R must be considered as a novel genetic subtype in patients with congenital neutropenia. The p.Arg308Cys mutation in CSF3R leads to altered G-CSF receptor glycosylation and surface expression and abrogated downstream signaling.
- 12 June 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (24) , 3811-3817
Inherited biallelic CSF3R mutations in severe congenital neutropenia
Severe congenital neutropenia (SCN) is characterized by low numbers of peripheral neutrophil granulocytes and a predisposition to life-threatening bacterial infections. We describe a novel genetic SCN type in 2 unrelated families associated with recessively inherited loss-of-function mutations in CSF3R, encoding the granulocyte colony-stimulating factor (G-CSF) receptor. Family A, with 3 affected children, carried a homozygous missense mutation (NM_000760.3:c.922C>T, NP_000751.1:p.Arg308Cys), which resulted in perturbed N-glycosylation and aberrant localization to the cell surface. Family B, with 1 affected infant, carried compound heterozygous deletions provoking frameshifts and premature stop codons (NM_000760.3:c.948_963del, NP_000751.1:p.Gly316fsTer322 and NM_000760.3:c.1245del, NP_000751.1:p.Gly415fsTer432). Despite peripheral SCN, all patients had morphologic evidence of full myeloid cell maturation in bone marrow. None of the patients responded to treatment with recombinant human G-CSF. Our study highlights the genetic and morphologic SCN variability and provides evidence both for functional importance and redundancy of G-CSF receptor-mediated signaling in human granulopoiesis. Key Points Biallelic mutations in CSF3R must be considered as a novel genetic subtype in patients with congenital neutropenia. The p.Arg308Cys mutation in CSF3R leads to altered G-CSF receptor glycosylation and surface expression and abrogated downstream signaling.
- Open Access
- 1 August 2013
- Published by Elsevier in Anales de Pediatría
- Vol. 79 (2) , 75-82
Resultados del trasplante de progenitores hematopoyéticos en hemoglobinopatías: talasemia maior y enfermedad drepanocítica
- 1 August 2013
- Published by Elsevier in Anales de Pediatría
- Vol. 79 (2) , 75-82
Open AccessResultados del trasplante de progenitores hematopoyéticos en hemoglobinopatías: talasemia maior y enfermedad drepanocítica
- 1 October 2012
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 49 (3-4) , 140-146
High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita
- 1 October 2012
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 49 (3-4) , 140-146
High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita
- 1 January 2011
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 33 (1) , e43-e45
Myeloproliferative Disorder in Noonan Syndrome
Children with Noonan syndrome (NS) are at increased risk of developing juvenile myelomonocytic leukemia (JMML) or a myeloproliferative disorder associated with NS (MPD/NS) resembling JMML in the first weeks of life; whereas JMML is an aggressive disorder requiring hematopoietic stem cell transplantation, MPD/NS may resolve without treatment and cases with spontaneous remission have also been reported. Two cases of NS with hematologic disorders are described. Diagnosis of the syndrome was confirmed by the identification of earlier reported germline missense mutations in the PTPN11 gene. Splenomegaly in 1 patient and leukocytosis, monocytosis and "in vitro" culture assays consistent with JMML in both were the most salient hematologic features. After a 24-month follow-up, these 2 infants continue to improve and JMML has been ruled out. Splenomegaly persists in 1 patient and monocytosis in both, but without signs of malignancy, thereby suggesting abnormal hematopoiesis or MPD/NS, as described in NS.
- 1 January 2011
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 33 (1) , e43-e45
Myeloproliferative Disorder in Noonan Syndrome
Children with Noonan syndrome (NS) are at increased risk of developing juvenile myelomonocytic leukemia (JMML) or a myeloproliferative disorder associated with NS (MPD/NS) resembling JMML in the first weeks of life; whereas JMML is an aggressive disorder requiring hematopoietic stem cell transplantation, MPD/NS may resolve without treatment and cases with spontaneous remission have also been reported. Two cases of NS with hematologic disorders are described. Diagnosis of the syndrome was confirmed by the identification of earlier reported germline missense mutations in the PTPN11 gene. Splenomegaly in 1 patient and leukocytosis, monocytosis and "in vitro" culture assays consistent with JMML in both were the most salient hematologic features. After a 24-month follow-up, these 2 infants continue to improve and JMML has been ruled out. Splenomegaly persists in 1 patient and monocytosis in both, but without signs of malignancy, thereby suggesting abnormal hematopoiesis or MPD/NS, as described in NS.
- 31 December 2010
- Published by Elsevier in Anales de Pediatría
- Vol. 73 (6) , 362.e1-362.e8
Documento de consenso de la Sociedad de Infectología Pediátrica sobre el tratamiento de la infección fúngica basado en la respuesta inmunológica
- 31 December 2010
- Published by Elsevier in Anales de Pediatría
- Vol. 73 (6) , 362.e1-362.e8
Documento de consenso de la Sociedad de Infectología Pediátrica sobre el tratamiento de la infección fúngica basado en la respuesta inmunológica
- 23 February 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 936-941
Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia
Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute lymphoblastic leukemia. Design and Methods The aim of this study was to ascertain whether the presence of minimal residual disease detected by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation is related to outcome in children acute lymphoblastic leukemia. Minimal residual disease was quantified by multiparametric flow cytometry at a median of 10 days prior to hematopoietic stem cell transplantation in 31 children (age range, 10 months to 16 years) with acute lymphoblastic leukemia. Thirteen patients were transplanted in first remission. Stem cell donors were HLA-identical siblings in 8 cases and matched unrelated donors in 23. Twenty-six children received a total body irradiation-containing conditioning regimen. According to the level of minimal residual disease, patients were divided into two groups: minimal residual disease-positive (≥0.01%) (n=10) and minimal residual disease-negative (P=0.004) and overall survival rates were 80% and 20%, respectively (P=0.005). Bivariate analysis identified pre-transplant minimal residual disease as the only significant factor for relapse and also for death (P<0.01). Conclusions The presence of minimal residual disease measured by multiparametric flow cytometry identified a group of patients with a 9.5-fold higher risk of relapse and a 3.2-fold higher risk of death than those without minimal residual disease. This study supports the strong relationship between pre-transplantation minimal residual disease measured by multiparametric flow cytometry and outcome following allogeneic hematopoietic stem cell transplantation and concur with the results of previous studies using polymerase chain reaction techniques.
- 23 February 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 936-941
Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia
Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute lymphoblastic leukemia. Design and Methods The aim of this study was to ascertain whether the presence of minimal residual disease detected by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation is related to outcome in children acute lymphoblastic leukemia. Minimal residual disease was quantified by multiparametric flow cytometry at a median of 10 days prior to hematopoietic stem cell transplantation in 31 children (age range, 10 months to 16 years) with acute lymphoblastic leukemia. Thirteen patients were transplanted in first remission. Stem cell donors were HLA-identical siblings in 8 cases and matched unrelated donors in 23. Twenty-six children received a total body irradiation-containing conditioning regimen. According to the level of minimal residual disease, patients were divided into two groups: minimal residual disease-positive (≥0.01%) (n=10) and minimal residual disease-negative (P=0.004) and overall survival rates were 80% and 20%, respectively (P=0.005). Bivariate analysis identified pre-transplant minimal residual disease as the only significant factor for relapse and also for death (P<0.01). Conclusions The presence of minimal residual disease measured by multiparametric flow cytometry identified a group of patients with a 9.5-fold higher risk of relapse and a 3.2-fold higher risk of death than those without minimal residual disease. This study supports the strong relationship between pre-transplantation minimal residual disease measured by multiparametric flow cytometry and outcome following allogeneic hematopoietic stem cell transplantation and concur with the results of previous studies using polymerase chain reaction techniques.